Cost-effective analysis of hepatitis a prevention in Ireland

OBJECTIVE:The purpose of this study was to determine the most cost-effective prevention strategy against hepatitis A virus (HAV) infection for healthcare workers and the general population at risk in Ireland.METHODS:Four prevention strategies were compared: active immunization with Havrix Monodose (1440E.U); screening for anti-HAV antibody and then vaccinating; passive immunization; screening for anti-HAV antibody and then passive immunization. The cost-effective ratio was calculated for each prevention strategy. Threshold analysis, sensitivity analysis, and model extension to include indirect cost from work days lost and secondary attack rates through horizontal transmission were also derived.RESULTS:The medical costs were lowest and the infection rate highest when no preventive action was taken. Vaccination was most cost effective when the prevalence of immunity was 45% or less, reducing the infection rate by 98% when compared to nonprevention. Screening before vaccination was most cost effective when the prevalence of immunity was greater than 45%. Passive immunization and screening before passive immunization were not comparable to the other strategies in cost effectiveness. Sensitivity analysis showed that the cost-effective ratio for vaccination was dependent on vaccine price, incidence of HAV, and prevalence of immunity in the target group. Extending the model to include indirect costs further increased the cost effectiveness of vaccination.CONCLUSION:The best cost-effective strategy relates to target group immunity. Where HAV immunity is 45% or less, vaccination is the strategy of choice and when immunity is greater than 45%, then screening followed by vaccination should be used. This study can be used to provide a framework within which choices can be made to achieve better health for less cost.

[1]  A. Shattock,et al.  Hepatitis a in urban Ireland , 1998, Irish journal of medical science.

[2]  A. Safary,et al.  Two year old hepatitis A vaccine is as good as new. , 1996, Vaccine.

[3]  R. Koff.  Seroepidemiology of hepatitis A in the United States. , 1995, The Journal of infectious diseases.

[4]  P Van Damme,et al.  Single dose inactivated hepatitis A vaccine: Rationale and clinical assessment of the safety and immunogenicity , 1994, Journal of medical virology.

[5]  P. van Damme,et al.  Cost‐effectiveness analysis of vaccination against hepatitis A in travellers , 1994, Journal of medical virology.

[6]  J. Roberts,et al.  Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers , 1994, BMJ.

[7]  C. Farrington,et al.  Age-specific antibody prevalence to hepatitis A in England: implications for disease control , 1994, Epidemiology and Infection.

[8]  T. Jefferson,et al.  An Economic Evaluation of the Introduction of Vaccination Against Hepatitis a in a Peacekeeping Operation: The Case of the United Nations Protection Force in Yugoslavia , 1994, International Journal of Technology Assessment in Health Care.

[9]  M. T. Jiménez de Anta,et al.  [A change in the epidemiologic pattern of hepatitis A in Spain]. , 1992, Medicina clínica (Ed. impresa).

[10]  M. Rapicetta,et al.  Decline in the exposure to hepatitis A and B infections in children in Naples, Italy. , 1989, Public health.

[11]  H. Margolis,et al.  The seroepidemiology of hepatitis A virus infection in Jordan. , 1988, Tropical gastroenterology : official journal of the Digestive Diseases Foundation.

[12]  R. Masterton,et al.  Hepatitis A immunity in British adults--an assessment of the need for pre-immunisation screening. , 1987, The Journal of infection.

[13]  D. Burke,et al.  Hepatitis A virus in stool during clinical relapse. , 1987, Annals of internal medicine.

[14]  S. Hadler,et al.  Hepatitis in day care centers: epidemiology and prevention. , 1986, Reviews of infectious diseases.

[15]  J. Escamilla,et al.  Hepatitis A in Peru. The role of children. , 1986, American journal of epidemiology.

[16]  D. Sarver.  Hepatitis in clinical practice. 1. Hepatitis A and B. , 1986, Postgraduate medicine.

[17]  G. Breguet,et al.  Serologic markers of hepatitis A and B in the population of Bali, Indonesia. , 1985, The American journal of tropical medicine and hygiene.

[18]  E. Schiff,et al.  Prolonged intrahepatic cholestasis secondary to acute hepatitis A. , 1984, Annals of internal medicine.

[19]  A. Mulley,et al.  Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. , 1982, The New England journal of medicine.

[20]  Polesky Hf,et al.  Comparison of viral hepatitis marker test methods based on AABB-CAP survey data. , 1981 .

[21]  S. Iwarson,et al.  Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups. , 1979, American journal of epidemiology.

[22]  T. Jefferson,et al.  Should British soldiers be vaccinated against hepatitis A? An economic analysis. , 1994, Vaccine.

[23]  P. van Damme,et al.  Cost-effectiveness analysis of hepatitis A prevention in travellers. , 1992, Vaccine.

[24]  H. Margolis,et al.  Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. , 1992, Vaccine.

[25]  J. Peetermans.  Production, quality control and characterization of an inactivated hepatitis A vaccine. , 1992, Vaccine.

[26]  R. Steffen,et al.  Vaccinations pour les voyages internationaux , 1989 .

[27]  M. Schultz.  Special-Use Immunobiologics for Travelers , 1989 .

[28]  O. James,et al.  A biphasic illness associated with acute hepatitis A virus infection. , 1986, Journal of hepatology.

[29]  J. Hoofnagle,et al.  Viral hepatitis and liver disease , 1984 .

[30]  H. Polesky,et al.  Comparison of viral hepatitis marker test methods based on AABB-CAP survey data. , 1981, American Journal of Clinical Pathology.

[31]  O. Weiland,et al.  Prevalence of antibody against hepatitis A in Sweden in relation to age and type of community. , 1980, Scandinavian journal of infectious diseases.